🇺🇸 Brimonidine Topical in United States

1,224 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Erythema — 275 reports (22.47%)
  2. Condition Aggravated — 208 reports (16.99%)
  3. Flushing — 165 reports (13.48%)
  4. Skin Burning Sensation — 128 reports (10.46%)
  5. Feeling Hot — 112 reports (9.15%)
  6. Rebound Effect — 107 reports (8.74%)
  7. Off Label Use — 92 reports (7.52%)
  8. Pain Of Skin — 49 reports (4%)
  9. Rash Macular — 48 reports (3.92%)
  10. Drug Ineffective — 40 reports (3.27%)

Source database →

Brimonidine Topical in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Brimonidine Topical approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Brimonidine Topical in United States?

University of Louisville is the originator. The local marketing authorisation holder may differ — check the official source linked above.